Literature DB >> 18974024

Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.

Lucas R Hoffman1, Hemantha D Kulasekara, Julia Emerson, Laura S Houston, Jane L Burns, Bonnie W Ramsey, Samuel I Miller.   

Abstract

BACKGROUND: Pseudomonas aeruginosa with mutations in the transcriptional regulator LasR chronically infect the airways of people with cystic fibrosis (CF), yet the prevalence and clinical implications of lasR mutant infection are unknown.
METHODS: In an exploratory study, we screened 166 P. aeruginosa isolates from 58 CF patients for LasR inactivation and mucoidy, and compared clinical characteristics among source patients.
RESULTS: lasR mutation prevalence was comparable to that of mucoidy, the best-described CF-adapted phenotype, but affected patients were on average approximately 2 years younger. In a regression analysis, lung function decline with age was worse among patients with lasR mutant infection than in those without, similar to the effect of mucoidy.
CONCLUSIONS: Culture positivity for lasR mutant P. aeruginosa may serve as a marker of early CF adaptive change of prognostic significance. Furthermore, as LasR inactivation alters susceptibility to antibiotics, infection with lasR mutant P. aeruginosa may impact response to therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18974024      PMCID: PMC2631641          DOI: 10.1016/j.jcf.2008.09.006

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  20 in total

1.  Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors.

Authors:  Morten Hentzer; Hong Wu; Jens Bo Andersen; Kathrin Riedel; Thomas B Rasmussen; Niels Bagge; Naresh Kumar; Mark A Schembri; Zhijun Song; Peter Kristoffersen; Mike Manefield; John W Costerton; Søren Molin; Leo Eberl; Peter Steinberg; Staffan Kjelleberg; Niels Høiby; Michael Givskov
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

2.  Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.

Authors:  J L Burns; R L Gibson; S McNamara; D Yim; J Emerson; M Rosenfeld; P Hiatt; K McCoy; R Castile; A L Smith; B W Ramsey
Journal:  J Infect Dis       Date:  2000-12-27       Impact factor: 5.226

Review 3.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

4.  Analysis of quorum sensing-deficient clinical isolates of Pseudomonas aeruginosa.

Authors:  J Andy Schaber; Nancy L Carty; Naomi A McDonald; Eric D Graham; Rajkumar Cheluvappa; John A Griswold; Abdul N Hamood
Journal:  J Med Microbiol       Date:  2004-09       Impact factor: 2.472

5.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

6.  Characterization of cell-to-cell signaling-deficient Pseudomonas aeruginosa strains colonizing intubated patients.

Authors:  Valérie Dénervaud; Patrick TuQuoc; Dominique Blanc; Sabine Favre-Bonté; Viji Krishnapillai; Cornelia Reimmann; Dieter Haas; Christian van Delden
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

7.  Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.

Authors:  Arnold L Smith; Stanley B Fiel; Nicole Mayer-Hamblett; Bonnie Ramsey; Jane L Burns
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

8.  The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic Pseudomonas aeruginosa.

Authors:  A L Barth; T L Pitt
Journal:  J Med Microbiol       Date:  1996-08       Impact factor: 2.472

9.  Transcription of quorum-sensing system genes in clinical and environmental isolates of Pseudomonas aeruginosa.

Authors:  Ségolène Cabrol; Anne Olliver; Gerald B Pier; Antoine Andremont; Raymond Ruimy
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490

10.  Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.

Authors:  Susan E H West; Lan Zeng; Bee Leng Lee; Michael R Kosorok; Anita Laxova; Michael J Rock; Mark J Splaingard; Philip M Farrell
Journal:  JAMA       Date:  2002-06-12       Impact factor: 157.335

View more
  128 in total

1.  Pseudomonas aeruginosa lasR mutant fitness in microoxia is supported by an Anr-regulated oxygen-binding hemerythrin.

Authors:  Michelle E Clay; John H Hammond; Fangfang Zhong; Xiaolei Chen; Caitlin H Kowalski; Alexandra J Lee; Monique S Porter; Thomas H Hampton; Casey S Greene; Ekaterina V Pletneva; Deborah A Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-01-24       Impact factor: 11.205

Review 2.  Pseudomonas aeruginosa AmpR: an acute-chronic switch regulator.

Authors:  Deepak Balasubramanian; Hansi Kumari; Kalai Mathee
Journal:  Pathog Dis       Date:  2015-02-26       Impact factor: 3.166

3.  Cooperation and cheating in Pseudomonas aeruginosa: the roles of the las, rhl and pqs quorum-sensing systems.

Authors:  Cara N Wilder; Stephen P Diggle; Martin Schuster
Journal:  ISME J       Date:  2011-03-03       Impact factor: 10.302

Review 4.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 6.  Virulence attenuating combination therapy: a potential multi-target synergy approach to treat Pseudomonas aeruginosa infections in cystic fibrosis patients.

Authors:  Elana Shaw; William M Wuest
Journal:  RSC Med Chem       Date:  2020-02-19

7.  A cell-cell communication signal integrates quorum sensing and stress response.

Authors:  Jasmine Lee; Jien Wu; Yinyue Deng; Jing Wang; Chao Wang; Jianhe Wang; Changqing Chang; Yihu Dong; Paul Williams; Lian-Hui Zhang
Journal:  Nat Chem Biol       Date:  2013-03-31       Impact factor: 15.040

8.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

9.  Evolutionary conservation of essential and highly expressed genes in Pseudomonas aeruginosa.

Authors:  Andreas Dötsch; Frank Klawonn; Michael Jarek; Maren Scharfe; Helmut Blöcker; Susanne Häussler
Journal:  BMC Genomics       Date:  2010-04-09       Impact factor: 3.969

10.  Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.

Authors:  Lucas R Hoffman; Anthony R Richardson; Laura S Houston; Hemantha D Kulasekara; Willm Martens-Habbena; Mikkel Klausen; Jane L Burns; David A Stahl; Daniel J Hassett; Ferric C Fang; Samuel I Miller
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.